|
Gene: TG |
Gene summary for TG |
Gene summary. |
Gene information | Species | Human | Gene symbol | TG | Gene ID | 7038 |
Gene name | thyroglobulin | |
Gene Alias | AITD3 | |
Cytomap | 8q24.22 | |
Gene Type | protein-coding | GO ID | GO:0006575 | UniProtAcc | P01266 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7038 | TG | Adj_PTCwithHT_6 | Human | Thyroid | HT | 7.30e-105 | -2.11e+00 | 0.02 |
7038 | TG | Adj_PTCwithHT_8 | Human | Thyroid | HT | 6.03e-06 | -2.18e-01 | 0.0267 |
7038 | TG | PTCwithHT_1 | Human | Thyroid | HT | 1.56e-31 | -1.52e+00 | 0.0238 |
7038 | TG | PTCwithHT_6 | Human | Thyroid | HT | 1.38e-104 | -2.12e+00 | 0.02 |
7038 | TG | PTCwithHT_8 | Human | Thyroid | HT | 2.54e-58 | -1.07e+00 | 0.0351 |
7038 | TG | PTCwithoutHT_2 | Human | Thyroid | PTC | 3.80e-11 | -3.56e-01 | 0.0419 |
7038 | TG | PTCwithoutHT_7 | Human | Thyroid | PTC | 4.95e-19 | -8.43e-01 | 0.0381 |
7038 | TG | male-WTA | Human | Thyroid | PTC | 1.56e-05 | 1.85e-01 | 0.1037 |
7038 | TG | nodule-WTA | Human | Thyroid | goiters | 1.11e-15 | 2.90e-01 | 0.0534 |
7038 | TG | PTC01 | Human | Thyroid | PTC | 1.01e-25 | 2.49e+00 | 0.1899 |
7038 | TG | PTC03 | Human | Thyroid | PTC | 2.57e-11 | 1.84e+00 | 0.1784 |
7038 | TG | PTC04 | Human | Thyroid | PTC | 7.44e-08 | 1.70e+00 | 0.1927 |
7038 | TG | PTC05 | Human | Thyroid | PTC | 7.32e-32 | 2.88e+00 | 0.2065 |
7038 | TG | PTC06 | Human | Thyroid | PTC | 8.06e-54 | 4.16e+00 | 0.2057 |
7038 | TG | PTC07 | Human | Thyroid | PTC | 5.54e-48 | 2.79e+00 | 0.2044 |
7038 | TG | ATC08 | Human | Thyroid | ATC | 1.04e-55 | -1.49e+00 | 0.0541 |
7038 | TG | ATC09 | Human | Thyroid | ATC | 2.30e-54 | -2.31e+00 | 0.2871 |
7038 | TG | ATC11 | Human | Thyroid | ATC | 5.27e-20 | -2.31e+00 | 0.3386 |
7038 | TG | ATC12 | Human | Thyroid | ATC | 2.29e-129 | -2.31e+00 | 0.34 |
7038 | TG | ATC13 | Human | Thyroid | ATC | 7.68e-130 | -2.30e+00 | 0.34 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ATC: Anaplastic thyroid cancer | |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00060918 | Breast | Precancer | generation of precursor metabolites and energy | 94/1080 | 490/18723 | 1.54e-25 | 1.64e-22 | 94 |
GO:00159808 | Breast | Precancer | energy derivation by oxidation of organic compounds | 70/1080 | 318/18723 | 8.33e-23 | 6.37e-20 | 70 |
GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
GO:00718269 | Breast | Precancer | ribonucleoprotein complex subunit organization | 48/1080 | 227/18723 | 2.68e-15 | 8.45e-13 | 48 |
GO:00226189 | Breast | Precancer | ribonucleoprotein complex assembly | 47/1080 | 220/18723 | 3.47e-15 | 1.03e-12 | 47 |
GO:00069799 | Breast | Precancer | response to oxidative stress | 70/1080 | 446/18723 | 1.59e-14 | 4.26e-12 | 70 |
GO:00064578 | Breast | Precancer | protein folding | 43/1080 | 212/18723 | 3.48e-13 | 7.45e-11 | 43 |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00485459 | Breast | Precancer | response to steroid hormone | 53/1080 | 339/18723 | 3.07e-11 | 3.66e-09 | 53 |
GO:00160329 | Breast | Precancer | viral process | 58/1080 | 415/18723 | 3.42e-10 | 3.16e-08 | 58 |
GO:00064588 | Breast | Precancer | 'de novo' protein folding | 16/1080 | 43/18723 | 8.14e-10 | 6.92e-08 | 16 |
GO:00190589 | Breast | Precancer | viral life cycle | 47/1080 | 317/18723 | 2.42e-09 | 1.99e-07 | 47 |
GO:00610778 | Breast | Precancer | chaperone-mediated protein folding | 19/1080 | 67/18723 | 4.22e-09 | 3.28e-07 | 19 |
GO:00709979 | Breast | Precancer | neuron death | 50/1080 | 361/18723 | 7.75e-09 | 5.70e-07 | 50 |
GO:00510848 | Breast | Precancer | 'de novo' posttranslational protein folding | 14/1080 | 39/18723 | 1.61e-08 | 1.12e-06 | 14 |
GO:00510858 | Breast | Precancer | chaperone cofactor-dependent protein refolding | 13/1080 | 34/18723 | 2.17e-08 | 1.47e-06 | 13 |
GO:00514029 | Breast | Precancer | neuron apoptotic process | 38/1080 | 246/18723 | 2.68e-08 | 1.75e-06 | 38 |
GO:00444039 | Breast | Precancer | biological process involved in symbiotic interaction | 42/1080 | 290/18723 | 3.40e-08 | 2.11e-06 | 42 |
GO:00521269 | Breast | Precancer | movement in host environment | 29/1080 | 175/18723 | 2.59e-07 | 1.28e-05 | 29 |
GO:00509006 | Breast | Precancer | leukocyte migration | 47/1080 | 369/18723 | 2.82e-07 | 1.39e-05 | 47 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
COL1A1 | ITGA1_ITGB1 | COL1A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A2 | ITGA1_ITGB1 | COL1A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A1 | ITGA1_ITGB1 | COL4A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A2 | ITGA1_ITGB1 | COL4A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A1 | ITGA1_ITGB1 | COL6A1_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A2 | ITGA1_ITGB1 | COL6A2_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A3 | ITGA1_ITGB1 | COL6A3_ITGA1_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A1 | ITGA2_ITGB1 | COL1A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL1A2 | ITGA2_ITGB1 | COL1A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A1 | ITGA2_ITGB1 | COL4A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL4A2 | ITGA2_ITGB1 | COL4A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A1 | ITGA2_ITGB1 | COL6A1_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A2 | ITGA2_ITGB1 | COL6A2_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
COL6A3 | ITGA2_ITGB1 | COL6A3_ITGA2_ITGB1 | COLLAGEN | Breast | ADJ |
LAMA2 | ITGA1_ITGB1 | LAMA2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMA4 | ITGA1_ITGB1 | LAMA4_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMB2 | ITGA1_ITGB1 | LAMB2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMB3 | ITGA1_ITGB1 | LAMB3_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMC1 | ITGA1_ITGB1 | LAMC1_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
LAMC2 | ITGA1_ITGB1 | LAMC2_ITGA1_ITGB1 | LAMININ | Breast | ADJ |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TG | SNV | Missense_Mutation | c.614N>C | p.Phe205Ser | p.F205S | P01266 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-JX-A3Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
TG | SNV | Missense_Mutation | c.4841N>A | p.Ser1614Asn | p.S1614N | P01266 | protein_coding | tolerated(0.55) | benign(0.094) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
TG | SNV | Missense_Mutation | c.1078N>A | p.Glu360Lys | p.E360K | P01266 | protein_coding | tolerated(0.26) | benign(0.005) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
TG | SNV | Missense_Mutation | novel | c.4698G>T | p.Leu1566Phe | p.L1566F | P01266 | protein_coding | deleterious(0.01) | possibly_damaging(0.771) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
TG | SNV | Missense_Mutation | novel | c.6299N>T | p.Ser2100Leu | p.S2100L | P01266 | protein_coding | deleterious(0.04) | benign(0.175) | TCGA-VS-A952-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
TG | SNV | Missense_Mutation | c.6815C>T | p.Ser2272Phe | p.S2272F | P01266 | protein_coding | deleterious(0.02) | benign(0.332) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
TG | SNV | Missense_Mutation | rs369705913 | c.5854C>T | p.Arg1952Trp | p.R1952W | P01266 | protein_coding | deleterious(0.03) | possibly_damaging(0.644) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TG | SNV | Missense_Mutation | rs145612902 | c.1907N>T | p.Cys636Phe | p.C636F | P01266 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TG | SNV | Missense_Mutation | c.4942N>A | p.Ala1648Thr | p.A1648T | P01266 | protein_coding | tolerated(0.28) | benign(0.009) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
TG | SNV | Missense_Mutation | c.1249N>A | p.Val417Met | p.V417M | P01266 | protein_coding | deleterious(0.02) | benign(0.401) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | RETINOIDS | 12182039 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | FDG | FLUDEOXYGLUCOSE-F18 | 10452315 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | BISPECIFIC ANTIBODY | 10433080 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PHENYTOIN | PHENYTOIN | 3935423 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PREDNISONE | PREDNISONE | 2745931 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | ALL-TRANS-RETINOIC ACID | 10946899 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | TGFBETA1 | 10770487,10194419 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | RETINOIC ACID | 11563543 | ||
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | PREDNISOLONE | PREDNISOLONE | 3427792,8636270 | |
7038 | TG | DRUGGABLE GENOME, HORMONE ACTIVITY | AMIODARONE | AMIODARONE | 8778159 |
Page: 1 2 3 4 |